{"id":"NCT00415519","sponsor":"Mitsubishi Tanabe Pharma Corporation","briefTitle":"Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III","officialTitle":"An Exploratory Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (Severity Classification III) in Double-Blind, Parallel-Group, Placebo-Controlled Manner","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-12","primaryCompletion":"2008-07","completion":"2008-07","firstPosted":"2006-12-25","resultsPosted":"2017-12-20","lastUpdate":"2017-12-20"},"enrollment":25,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Amyotrophic Lateral Sclerosis (ALS)"],"interventions":[{"type":"DRUG","name":"MCI-186","otherNames":["Edaravone","Radicut"]},{"type":"DRUG","name":"Placebo of MCI-186","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective of this study is to evaluate the efficacy of 60mg of MCI-186 via intravenous drip once a day in patients with ALS whose severity is classified as grade III, based on the changes in the revised ALS functional rating scale (ALSFRS-R) scores after 24 weeks administration in double-blind, placebo-controlled manner. And in addition, this study will be performed to examine the safety of MCI-186 to ALS patients who met severity classification III.","primaryOutcome":{"measure":"Change From Baseline in Revised ALS Functional Rating Scale (ALSFRS-R) Score in Full Analysis Set (FAS) Population at 24 Weeks","timeFrame":"baseline and 24 weeks","effectByArm":[{"arm":"MCI-186","deltaMin":-6.52,"sd":1.78},{"arm":"Placebo of MCI-186","deltaMin":-6,"sd":1.83}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":6},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["28872915"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":13},"commonTop":["Headache","Diarrhoea","Gait disturbance","Nasopharyngitis","Upper respiratory tract inflammation"]}}